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holocarboxylase synthetase, but is not a target for biotinylation
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aDepartment of Nutrition and Health Sciences, University of Nebraska at Lincoln.
bDepartment of Chemistry, University of Nebraska-Lincoln.
Abstract
Holocarboxylase synthetase (HCS) catalyzes the binding of biotin to lysines in carboxylases and
histones in two steps. First, HCS catalyzes the synthesis of biotinyl-5′-AMP; second, the biotinyl
moiety is ligated to lysine residues. It has been proposed that step two is fairly promiscuous, and that
protein biotinylation may occur in the absence of HCS as long as sufficient exogenous biotinyl-5′-
AMP is provided. Here, we identified a novel polypeptide (Syn67) with a basic patch of lysines and
arginines. Yeast-two-hybrid assays and limited proteolysis assays revealed that both N- and C-termini
of HCS interact with Syn67. A potential target lysine in Syn67 was biotinylated by HCS only after
arginine-to-glycine substitutions in Syn67 produced a histone-like peptide. We identified a Syn67
docking site near the active pocket of HCS by in silico modeling and site directed mutagenesis.
Biotinylation of proteins by HCS is more specific than previously assumed.
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1. Introduction
Biotin is a water-soluble vitamin that serves as a coenzyme for 3-methylcrotonyl-CoA
carboxylase, pyruvate carboxylase, propionyl-CoA carboxylase, and acetyl-CoA carboxylases
1 and 2 [1]. Carboxylases play essential roles in macronutrient metabolism. Biotin is also
covalently attached to at least 11 distinct lysine (K) residues in histones H2A, H3, and H4,
including biotinylation of K12 in histone H4 (H4K12bio) [2–5]. Covalent modifications of
histones are known to play crucial roles in gene regulation, DNA repair, and chromatin structure
[2]. H4K12bio has been linked to the repression of genes [3,4] and retrotransposons [5], the
cellular response to DNA damage [6], and also is enriched in telomeric repeats and
pericentromeric alpha satellite repeats [3,7].
Attachment of biotin to both carboxylases and histones is mediated by holocarboxylase
synthetase (HCS, EC 6.3.4.10) [4,8,9]. The following four domains have been identified and
characterized in human HCS: N-terminal domain, central domain, linker domain, and C-
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terminal domain [10]. Both N- and C-termini of HCS participate in substrate recognition
[10]. The central domain in HCS contains binding sites for both ATP and biotin [11–13]. The
linker domain might play a role in conferring the flexibility needed for HCS to interact with a
diverse group of substrates for biotinylation [10]. Mutations and knockdown of HCS decreases
the abundance of biotinylated carboxylases and histones [4,8,9,14,15], leading to abnormal
patterns of gene expression [4,9] and phenotypes such as altered life span and stress resistance
[9,16].
HCS-mediated biotinylation of carboxylases and histones requires ATP and proceeds in two
steps [17]. In the first step, HCS catalyzes the synthesis of biotinyl-5′-AMP. In the second step,
the biotinyl moiety is conjugated to distinct lysine residues in target proteins. Recently it was
proposed that the second step may occur in the absence of HCS, if synthetic biotinyl-5′-AMP
is provided [18]. If true, this could be a mechanism to explain biotinylation of proteins as
diverse as carboxylases and histones, but it would also make it somewhat difficult to explain
why only some of the many lysines in histones are biotinylated [19]. Here, we used various
molecular biology techniques and in silico modeling to test the hypothesis that not all the
proteins and polypeptides that interact with HCS are targets for biotinylation, but that
carboxylase- and histone-like structures are preferred HCS targets.
2. Materials and Methods
2.1 Y2H assays
Two independent Y2H assays were conducted to identify HCS-interacting proteins, following
our previously published protocols for high-stringency conditions [10]. Briefly, a human liver
cDNA library was fused to a Gal4 activation domain (Gal4AD) and served as prey in Y2H
assays (pGADT7 vector; Clontech, Mountain View, CA). Full-length human HCS (GenBank
accession #D23672) was fused to a Gal4 binding domain (BD) to produce vector pGBKT7-
HCS [10], which was used as bait. In previous studies we demonstrated that pGBKT7-HCS
does not auto-activate reporter genes in Y2H assays and is not toxic for S. cerevisiae strain
AH109 [10]. Also in previous studies we demonstrated biological activity of human HCS in
yeast [10]. Growth of mated yeast colonies was monitored for up to 21 d. Sterile tubes
containing 20 mL of SD/-Leu broth were inoculated with recovered yeast colonies and grown
for 72 h on an orbital shaker (200 rpm) at 30°C. Cells were collected by centrifugation at 2880
g at 4°C and yeast plasmids were isolated using the YEASTMAKER yeast plasmid isolation
kit (Cat. # PT3049-1; Clontech) or the Zymoprep II kit (Cat. # D2004; Zymo Research, Orange,
CA) following the manufacturers’ protocols. A total of 425 clones that interacted with HCS
were recovered in the two Y2H assays; 62 clones were chosen for further analysis, preference
being given to clones from colonies that were visible within less than 14 d of incubation. Eluted
plasmids (10 µL) were used to transform One Shot TOP10 chemically competent E. coli cells
(Invitrogen, Carlsbad, CA) for subsequent plasmid preparation (QIAprep Spin Miniprep kit,
Qiagen, Valencia, CA) and DNA sequencing. Nucleotide sequences were converted to protein
sequences, using the ExPASy DNA translation tool [20]. One polypeptide comprising 67 amino
acids interacted strongly with HCS and appeared in both Y2H assays (see Results); this
polypeptide was named Syn67 and became the focus of this study. Yeast was co-transformed
with Syn67-Gal4AD, and either pGBKT7 vector (empty Gal4BD) or pGBKT7-HCS to confirm
HCS:Syn67 interactions in a targeted Y2H assay.
Interactions of Syn67-Gal4AD with the following truncation constructs of HCS-Gal4 BD were
investigated to identify HCS domains that interact with Syn67: pGBKT7–HCS1–446 (HCS N-
terminal domain, M1–F446), pGBKT7–HCS471–575 (central domain, F471–S575), pGBKT7–
HCS610–668 (linker domain, T610–V668), pGBKT7–HCS669–718 (C-terminal domain, H669–
R718), pGBKT7-HCS_Ndel (deletion of the N-terminal domain M1-F446), and pGBKT7-
HCS_Cdel (deletion of the C-terminal domain H669-R718) [10]. Plates were monitored daily
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for appearance of colonies. The time of appearance was recorded accordingly as an indicator
for the strength of interactions.
2.2 Recombinant HCS, Syn67, and p67
The Syn67 insert in Syn67-Gal4AD was PCR amplified using primers 5’-
tggagggatccatggagtacccatacg-3’ (forward) and 5’-tatatgtcgaccttattggggagggggtg-3’ (reverse)
and cloned using vector pET-30a(+) (Novagen, Madison, WI). PCR products and pET-30a(+)
were digested with BamHI and SalI and gel purified prior to overnight ligation, to produce
plasmid Syn67-pET. The identity of Syn67-pET was confirmed by sequencing before
ArcticExpress (DE3)RP E. coli competent cells (Cat., #230194, Stratagene, La Jolla, CA) were
transformed with the plasmid. Recombinant Syn67 was purified using His Trap FF columns
and an AKTA protein purification system as described for p67 [19]. Protein extracts were
resolved on Novex 16% Tricine gels (Invitrogen) and stained with Coomassie blue to confirm
expression of a polypeptide of the expected size (13 kDa for his-tagged Syn67). Purified Syn67
was stored at −20°C in elution buffer.
The polypeptide p67 comprises the 67 C-terminal amino acids in human propionyl-CoA
carboxylase, including the biotin-binding site K669 [11]. p67 is a well-established substrate
for studies of HCS [11,13]. Recombinant p67 was produced as described previously [19]. p67
is a target for biotinylation by the HCS ortholog in E. coli, BirA, and the biotin-containing
fraction of p67 was removed using avidin beads [19].
Recombinant human HCS was prepared as described (B. Bao et al., submitted) with minor
modifications. Briefly, a clone coding for full-length human HCS was obtained from Yoichi
Suzuki (Tohoku University, Sendai, Japan) [21]. SacI and EcoRI restriction sites were inserted
by PCR, using forward primer 5’-catatgagctcatggaagatagactccac-3’ and reverse primer 5’-
ctaatgaattcttaccgccgtttggggaggatg-3’. PCR products were ligated into pSTBLUE-1 AccepTor
vector (Novagen, Madison, WI), digested with SacI and EcoRI, and subcloned into vector
pRSET A (Novagen), thereby fusing a his·tag to the N-terminus of HCS. The plasmid was
named “HCS- pRSET A” and codes for a fusion protein of 82 kDa; its identity was verified
by sequencing. ArcticExpress™ (DE3) competent cells (Stratagene, La Jolla, CA) were
transformed with HCS- pRSET A and grown overnight at 37°C in 10 mL LB broth containing
20 mg/L gentamycin and 50 mg/L ampicillin. Cultures were expanded to 1 L and grown at 30°
C for about 5 h to an optical density of 0.3 to 0.6 at 600 nm. Isopropyl-beta-D-
thiogalactopyranoside was added for a final concentration of 1 mM and cultures were continued
at 12°C for 24 h. Cell pellets were collected by centrifugation at 2700 g for 10 min, and
resuspended in 50 mM Tris buffer (pH 7.5) with protease inhibitor cocktail set III (Calbiochem,
Gibbstown, NJ; Cat. # 539134). Samples were sonicated on ice and cell debris was removed
by centrifugation. HCS fusion protein was purified using His Trap FF columns on an AKTA
protein purification system according to manufacturer’s instructions (GE Healthcare). HCS in
the column fractions was identified by gel electrophoresis, Coomassie blue staining, anti-
His·tag antibody (Novagen), and an antibody to the C-terminus in human HCS [22].
2.3 Limited proteolysis assays
Limited proteolysis experiments were conducted as described [23] to confirm that HCS
interacts with Syn67. In proteolysis assays, interactions between two proteins slow proteolytic
degradation to an extent that is detectable by Western blot analysis. Briefly, 5.85 µg
recombinant Syn67 was pre-incubated in the presence or absence of 34 µg recombinant HCS
in 50 µL of 75 mM Tris acetate buffer (pH 7.5), 0.3 mM dithiothreitol, and 45 mM MgCl2 at
37°C for 2 h to allow for binding of HCS to Syn67. Ten microliters were collected as baseline
value, and 200 ng trypsin (Sigma; Cat. # T6567, St. Louis, MO) was added to the remaining
solution. Incubation was continued at 37°C and 10-µL aliquots were collected at timed
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intervals. Proteolysis was stopped by adding NuPAGE sample buffer (Invitrogen) and heating
at 95°C for 10 min. Proteins were resolved using 4–12% NuPAGE Bis-Tris gels and stained
with silver stain (SilverQuest; Invitrogen).
2.4 Site-directed mutagenesis of HCS
A large number of mutations have been identified in human HCS from various ethnic
backgrounds [14,21]; some of these mutation decrease HCS activity by >99% compared with
wild-type HCS and require treatment of afflicted individuals with pharmacological doses of
biotin [24,25]. Here we tested four of the most common HCS mutations to determine whether
they affect the interactions of HCS with Syn67. The following mutants were created using the
Gene Tailor Site-Directed Mutagenesis System and the manufacturer’s protocol (Invitrogen);
PCR reactions were conducted using high fidelity platinum taq polymerase (Invitrogen) and
pGBKT7-HCS as a template: (a) The L237P mutation is caused by a C997T transition in the
HCS coding region [14,26] and was created using primers 5’-
accagaagttcatggcctatccctctcagggag-3’ (forward) and 5’-
ataggccatgaacttctggtacaggtcttc-3’ (reverse); (b) The D571N mutation is caused by a G1998A
transition in the HCS coding region [24,25], and was created using primers 5’-
tacgagtgaagtggcccaacaacatttattacag-3’ (forward) and 5’-
gttgggccacttcactcgtaagttgatatc-3’ (reverse); (c) The R508W mutation is caused by a C1522T
transition in the HCS coding region [21], and was created using primers 5’-
ggcagaccgagggcaaaggatggggagggaatg-3’ (forward) and 5’-
tcctttgccctcggtctgccgggccgcgat-3’ (reverse); and (d) the G581S mutant is caused by a G1741A
transition in the HCS coding region [21,25,27] and was created using primers 5’-
acagtgacctcatgaagatctccggagttctgg-3’ (forward) and 5’-
gatcttcatgaggtcactgtaataaatatc-3’ (reverse). Briefly, 2 µL of mutagenesis mixture were
transformed into chemically competent MAX Efficiency® DH5α-T1R cells (F- φ80lacZΔM15
Δ(lacZYA-argF)U169 recA1 endA1 hsdR17(rk−, mk+) phoA supE44 thi-1 gyrA96 relA1
tonA) before plating on LB plates supplemented with ampicillin. The following bait plasmids
were recovered and corresponded to the four mutants named above: pGBKT7-HCSL237P,
pGBKT7-HCSD571N, pGBKT7-HCSR508W, and pGBKT7-HCSG581S. Interactions of mutants
with Syn67-Gal4AD were investigated using Y2H assays as described above.
2.5 Molecular modeling of HCS:partner (Syn67 and p67) interactions
3D models of HCS and p67 were predicted as described in our previous studies [10,28]. The
structure of Syn67 was predicted using the Phyre server and Tk-subtilisin propeptide as a
template (protein database ID = 2z57) [29]. Protein-protein interaction between HCS and its
two substrates p67 and Syn67 were modeled using Patchdock [30] and results were refined
using FireDock [31]. Modeling of interactions was completed by visual inspection of
representations generated by PyMol [32] and Deep View [33].
2.6 Biotinylation of Syn67 and Syn67-like peptides by recombinant human HCS
Syn67 contains one lysine residue embedded in a patch of arginine residues, creating a potential
target site for biotinylation by HCS (see Results). Recombinant human HCS, Syn67, and p67
were prepared as described above. Biotinylation assays were conducted as described in our
previous studies [19], using up to 34 µg of HCS and up to 5.85 µg of Syn67 per sample; p67
was used as positive control at an amount of 0.75 µg per sample. Proteins were resolved by
gel electrophoresis and peptide-bound biotin was visualized using either IRDye® 800CW
streptavidin or anti-biotin polyclonal antibodies (Abcam) and a LI-COR Odyssey infrared
imaging system (LI-COR, Lincoln, NE).
In some biotinylation assays, recombinant Syn67 was replaced with the following synthetic
Syn67-based peptides to identify amino acid residues that facilitate or hinder biotinylation of
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Syn67 (see Results): (a) NRSRRKECFRS = truncated variant of Syn67, containing the lysine
residue that is a potential target for biotinylation by HCS; (b) NRSGGKECFRS = histone-like
variant of Syn67, in which glycines were substituted for arginines adjacent to the lysine residue;
(c) NRSRRAECFRS = negative control, in which the lysine in Syn67 was replaced with an
alanine; and (d) NRSAMKMCFRS = p67-like variant of Syn67 in which AMKM was
substituted for RRKE to create the canonical biotinylation site in carboxylases [12]. All
peptides were acetylated at the N-terminus to prevent biotinylation of the α-amino group.
Peptides were purchased from AnaSpec (San Jose, CA) and identities and purities were
confirmed by mass spectrometry and HPLC, respectively, by the manufacturer.
3. Results
3.1 Interactions between human HCS and the Syn67 polypeptide
Two Y2H assays were conducted independently, and consistently suggested that human HCS
interacts with a polypeptide that was subsequently named Syn67. Syn67 comprises 67 amino
acids, including a lysine near the C-terminus as a potential target site for biotinylation by HCS
(Fig. 1). The lysine is embedded in a basic patch of arginines, creating an environment
suspected to favor biotinylation by HCS [18].
The interaction between full-length HCS and Syn67 was among the strongest interactions seen
in our Y2H screening experiments; colonies became visible within only 2–3 days of incubation
of mated yeast (Fig. 2). No auto-activation of the reporter genes or non-specific binding to the
Gal4 BD was observed for this peptide (data not shown). Both N- and C-termini in HCS
interacted with Syn67, whereas central domain and linker domain did not interact (Fig. 2). The
importance of the N- and C-termini in HCS for interactions with Syn67 were confirmed in
targeted Y2H assays of truncated and mutant HCS as described below.
Physical interactions between HCS and Syn67 were confirmed by limited proteolysis assay,
using recombinant full-length HCS and recombinant Syn67 (Fig. 3). If HCS was digested with
trypsin in the presence of Syn67, HCS digestion was delayed by 10–15 minutes compared with
Syn67-free controls. The reader should note that various modifications of the digestion protocol
were tested; Syn67 always slowed but never prevented the degradation of a large fraction of
rHCS in incubation mixtures. Collectively, these observations suggest that Syn67 recognizes
the three-dimensional fold of full-length HCS by interacting with at least two HCS domains
(N- and C-termini) known to play important roles in interactions with biotinylation targets
[10].
3.2 Biotinylation of Syn67
Syn67 is not a target for biotinylation by HCS. If recombinant Syn67 was incubated with
recombinant HCS and cofactors for biotinylation for up to 24 h, no Syn67-bound biotin was
detectable with streptavidin (Fig. 4, lane A). Other incubation periods (12–18 h) were also
tested, but also produced no signal (data not shown). Previous studies suggested that
recombinant proteins that are targets for biotinylation by HCS, e.g. p67, undergo biotinylation
by BirA in E. coli [19]. However, recombinant Syn67 was not biotinylated by BirA in E.
coli (Fig. 4, lane B). Recombinant p67, a well-known HCS and BirA substrate [11,19,34], was
deprived of the biotin-containing fraction by avidin beads before biotinylation assay (Fig. 4,
lane C); biotin-depleted p67 was used as positive control in biotinylation assays and produced
a strong signal after only 45 min of incubation with HCS (Fig. 4, lane D).
Syn67 became a target for biotinylation by HCS only after the amino acid sequence was altered
to produce a histone-like variant of Syn67. If a truncated variant of Syn67 (peptide
NRSRRKECFRS) was incubated with HCS and cofactors for enzymatic biotinylation, no
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peptide-bound biotin was detectable if probed with anti-biotin and streptavidin (Fig. 5, lane
A). If arginines adjacent to the lysine residue in Syn67 were substituted with glycines to
produce a sequence reminiscent to that in histones (peptide NRSGGKECFRS), the peptide
became substrate for biotinylation by HCS (Fig. 5, lane B). If the lysine residue in Syn67 was
replaced with an alanine (peptide NRSRRAECFRS, negative control), no biotin was detectable
by anti-biotin and streptavidin (Fig. 5, lane C). Finally, a p67-like variant of Syn67 was created
by substituting AMKM for RRKE; the p67-like variant of Syn67 also was no good substrate
for biotinylation by HCS (Fig. 5, lane D). The latter is not too surprising, given that previous
studies suggested a minimum length of 67 amino acids for carboxylase-based peptides to
become HCS substrates [11].
3.3 Molecular modeling of HCS interactions
HCS, p67, and Syn67 were subjected to molecular modeling. The HCS model spanned the
region between E393 and D715. The root mean square deviation (RMSD) between the biotin
protein ligase in E. coli, BirA, as a template and the HCS model was 0.52 Å, as previously
reported [10]. The p67 model covered R1 to E66 with RMSD at 0.39 Å and contained six β-
strands. Lysines were located at the ends of β-strands. For Syn67, the model covered M13 to
E59 with the RMSD being 0.45 Å. The model contained an α-helix from A43 to V55, short
two β-strands, and a major loop. The only potential biotinylation target in Syn67, K58, resides
in the loop (Fig. 6). Generally, models with RMSD less than 1 Å are considered reliable for
prediction [35,36].
Our previous studies revealed two potential binding sites for p67 in HCS [10]; predicted
binding energies are −44 units for site A and −69 units for site B (Fig. 7). Three potential Syn67
binding sites were predicted in HCS (Fig. 7); two of these sites (denoted A and B) are shared
with p67. Syn67 binding energies at sites A, B, and C were estimated to be −51, −47, and −44
units, respectively. These binding energies are similar to those calculated for antigen-antibody
interactions [31]. The following residues in HCS are predicted to play important roles in the
three Syn67-binding sites: (a) site A = R508-N511, Q533-Q542, P569-N570, V585-F594,
G677-S678, and D710-G711; (b) site B = E444-S448, L453-R457, R501-Q502, V512-C519,
and T605-E619; and (c) site C = V407-L420, N452-I455, and S607-I613.
3.4 Effects of HCS mutations on interactions with Syn67
Targeted Y2H assays with HCS mutants revealed that truncations and mutations in the
predicted Syn67-binding sites substantially decreased the strength of interaction. Mated yeast
transformed with Syn67 and full-length HCS produced visible colonies in as little as 2–3 d
(Fig. 8A). If the C-terminus of HCS was deleted, interaction with Syn67 was abolished (Fig.
8B), consistent with the involvement of the C-terminus in substrate recognition described
above. Likewise, if the N-terminus of HCS was deleted, it took about 15 d of incubation for
colonies to become faintly visible (Fig. 8D). Interactions with Syn67 were also abolished in
the D571N and R508W mutants (Fig. 8 E and F), even if incubation was extended to 21 d (not
shown). These two mutations reside in or within immediate proximity to the Syn67 docking
site A (see above), suggesting that site A, rather than sites B and C, is the substrate docking
site in HCS. Two other mutations that are commonly found in human HCS (G581S and L237P)
also resulted in decreased interactions with Syn67, but the effects were smaller than those seen
for the D571N and R508W mutants. Colonies of the G581S mutant became visible after about
3–4 days of incubation (Fig. 8C), whereas colonies of the L237P mutant became visible after
7–8 d of incubation (Fig. 8G).
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4. Discussion
To the best of our knowledge this is the first report of a protein or polypeptide interacting with
HCS without being biotinylated. The polypeptide identified here, Syn67, mimics the binding
characteristics of a known HCS substrate, p67. Both Syn67 and p67 bind to the central domain
of HCS near the active pocket, and for both polypeptides the N- and C-termini of HCS are
important for binding ([10], and this study). The importance N- and C-termini for Syn67
binding is consistent with the recently solved structure of Aquifex aeolicus biotin protein ligase,
revealing that N- and C-terminal domains form a cavity involved in catalysis [37]. The confines
of the Syn67-binding site in the central domain are being predicted as R508-N511, Q533-Q542,
P569-N570, V585-F594, G677-S678, and D710-G711, based on in silico modeling and site-
directed mutagenesis studies. This study sheds important light on a current debate in
epigenetics, where it has been suggested that HCS physically interacts with histone H2A, and
that the subsequent biotinylation of histone H2A depends on the intermediate biotinyl-5’-AMP
but not directly on HCS [18]. This could be mis-construed as a phenomenon where biotinylation
of lysines in histones might occur whenever a free ε-amino group is available, rather than being
linked to specific biological readouts. Non-specific biotinylation of lysine residues in histones
is not consistent with the existing dogma in epigenetics that distinct histone marks typically
have distinct biological readouts [2]. For example, evidence has been provided that
biotinylation of K12 in histone H4 participates in the repression of transposable elements,
whereas other histone biotinylation marks appear not to play a role in this phenomenon [5].
We believe that a very careful analysis of HCS-mediated biotinylation events is needed, and
that Syn67 might prove a useful tool in such studies.
The present study already offered some useful insights into biotinylation of lysine residues by
HCS. In the Syn67 polypeptide, a lysine residue resides in a patch of basic amino acids. Despite
physically interacting with HCS, the lysine residue is not a target for biotinylation. Only after
the amino acid sequence in Syn67 was altered by substituting two glycines for arginines to
create a histone-like peptide, became Syn67 a target for biotinylation by HCS. We interpret
this observation as HCS specifically biotinylating distinct lysine residues in histones (and
carboxylases). The majority of the lysine residues in histones that are known to be targets for
biotinylation reside in glycine-rich patches [38,39], suggesting that glycines create an
environment favorable for lysine biotinylation. It is currently unknown whether this is due to
the small size of glycines or to the absence of D- and L-isomers. The former decreases steric
hindrance, the latter might create additional flexibility in the substrate molecule to fit into the
active site of HCS. Please note that we did not formally exclude the possibility that HCS might
also biotinylate some proteins other than histones and carboxylases.
We cannot formally exclude the possibility that the His-tag in rHCS might have influenced
interactions with Syn67 in limited proteolysis assays and Syn67 biotinylation studies.
Importantly, this is not the case in Y2H assays were untagged HCS, HCS domains, and HCS
mutants were used. Moreover, in previous studies we demonstrated that HCS (and its microbial
ortholog BirA) interacts physically with histone H3 to mediate biotinylation of lysines 9, 18,
and 23 ([19,39], B. Bao, et al., submitted)). In these previous studies, HCS interacted strongly
with histone H3, regardless of whether experiments were conducted using His-tagged, GST-
tagged, GFP-tagged, or endogenous HCS. Given that both tagged and untagged HCS revealed
an affinity of HCS for Syn67, we are confident that the reported interaction is real.
The biological importance of Syn67 is currently unknown. Syn67 was identified when
screening a human liver cDNA library for HCS-binding proteins. A database search revealed
no known biological functions for Syn67 or related proteins. Meanwhile, Syn67 might be a
useful analytical tool in the following applications. First, the histone-like Syn67 peptide might
prove a useful tool in the development of HCS assays, which currently depend on the
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production of recombinant p67, followed by treatment with avidin beads to remove
endogenously biotinylated p67 [19]. Second, site-directed mutagenesis of individual amino
acid residues in Syn67, followed by Y2H assays, can generate rapid insights into which residues
are important for binding to HCS. Third, Syn67-drug conjugates might prove useful tools to
deliver drugs directly to HCS, e.g., to alter the epigenome in the cell nucleus.
The lack of a good template for modeling of the 3D structure of HCS causes some uncertainty
regarding our Syn67 docking predictions. In this study, the 3D structure of BirA from E. coli
was used as a template to model HCS. Both BirA and HCS share a high degree of functional
similarity [19], the size of the two proteins and the amino acid sequence are considerably
different. Importantly, BirA lacks major portions of the N-terminus of HCS [40], making it
impossible to reliably predict the conformation of the HCS N-terminus. Currently, no X-ray
crystallography data are available for HCS. In this study, we limited HCS modeling to the
sequence spanning amino acids E393-D715 in order to maintain a high level of stringency.
Abbreviations used
Ade adenine
Arg arginine
Gal4AD Gal4 Activation domain
Gal4BD Gal4 DNA binding domain
HCS holocarboxylase synthetase
His histidine
Kan kanamycin
Leu leucine
Lys lysine
PPI protein–protein interactions
RMSD root mean square deviation
Y2H yeast-two-hybrid
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Figure 1.
The Syn67 polypeptide contains one lysine residue (gray box), embedded in a patch of basic
amino acids (underlined).
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Figure 2.
The N- and C-termini in human HCS interact with Syn67 in yeast-two-hybrid assays. N-
terminal domain, central domain, linker domain, C-terminal domain, and full-length HCS were
investigated. (A) Plate layout. (B) Growth of the yeast host strain AH109 transformed with
Gal4BD-HCS domains and Gal4AD-Syn67 on SD/-Leu,-Trp, +Kan medium to confirm co-
transformation with both plasmids. (C) Activation of reporter genes in AH109 yeast caused by
HCS:Syn67 interactions.
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Figure 3.
Limited proteolysis assay of HCS. Recombinant HCS and Syn67 were pre-incubated to allow
for interactions to occur, followed by tryptic digestion (left panel); controls were prepared by
omitting Syn67 and also digested with trypsin (right panel). Aliquots were collected at timed
intervals, resolved by gel electrophoresis, and stained with silver stain. M = molecular weight
markers.
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Figure 4.
Biotinylation of Syn67 and Syn67-like peptides by recombinant human HCS: (A) Syn67 is not
a target for biotinylation by HCS; (B) Recombinant Syn67 does not contain endogenous biotin;
(C) Recombinant p67 was biotin-depleted by using avidin beads and incubated in the absence
of HCS (negative control); (D) Biotinylation of recombinant p67 by recombinant human HCS
(positive control). M = molecular weight markers.
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Figure 5.
A histone-like variant of Syn67 becomes a target for biotinylation by HCS. Synthetic peptides
were incubated with recombinant human HCS and co-factors for biotinylation. Samples in the
top panel were probed with anti-biotin; samples in the bottom panel were probed with
streptavidin. (A) truncated variant of Syn67 (peptide NRSRR ECFRS); (B) histone-like
variant of Syn67 (peptide NRSGG ECFRS); (C) negative control (peptide
NRSRRAECFRS); and (D) p67-like variant of Syn67 (peptide NRSAM MCFRS). The
potential target site for biotinylation is shaded in gray; amino acid substitutions are underlined.
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Figure 6.
Prediction of three-dimensional structures of p67 and Syn67. (A) Syn67 (magenta); (B) p67
(blue); (C) superimposed Syn67 and p67.
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Figure 7.
Prediction for p67 and Syn67 binding sites in HCS. HCS (white surface model) has two
potential binding sites for p67 (blue; sites labeled A and B) and three potential binding sites
for Syn67 (magenta; sites labeled A, B, and C). G581 is positioned in the back of the HCS/
Syn67 complex and cannot be seen from this perspective. The approximate location of G581
in the back of the model is indicated by a dashed line. L237 is not shown because the depicted
model is based on amino acid residues 373 – 715 in human HCS.
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Figure 8.
Effects of HCS truncations and mutations on interactions with Syn67. The yeast host strain
AH109 was transformed with Gal4AD-Syn67, Gal4BD-HCS, or the following truncated or
mutant variants of HCS, and grown on SD/-Leu,-Trp,-Ade,-His,+Kan medium: (A) wild-type
HCS; (B) truncated HCS lacking the C-terminus; (C) HCS G581S mutant; (D) truncated HCS
lacking the N-terminus; (E) HCS D571N mutant; (F) HCS R508 mutant; and (G) HCS L237P
mutant. (H) Positive control (interaction of p53 with T-antigen).
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